Cargando…

Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide

Type 2 diabetes makes up approximately 85% of all diabetic cases and it is linked to approximately one-third of all hospitalisations. Newer therapies with long-acting biologics such as glucagon-like peptide-1 (GLP-1) analogues have been promising in managing the disease, but they cannot reverse the...

Descripción completa

Detalles Bibliográficos
Autores principales: Abeer, Muhammad Mustafa, Meka, Anand Kumar, Pujara, Naisarg, Kumeria, Tushar, Strounina, Ekaterina, Nunes, Rute, Costa, Ana, Sarmento, Bruno, Hasnain, Sumaira Z., Ross, Benjamin P., Popat, Amirali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723263/
https://www.ncbi.nlm.nih.gov/pubmed/31430872
http://dx.doi.org/10.3390/pharmaceutics11080418
_version_ 1783448727289069568
author Abeer, Muhammad Mustafa
Meka, Anand Kumar
Pujara, Naisarg
Kumeria, Tushar
Strounina, Ekaterina
Nunes, Rute
Costa, Ana
Sarmento, Bruno
Hasnain, Sumaira Z.
Ross, Benjamin P.
Popat, Amirali
author_facet Abeer, Muhammad Mustafa
Meka, Anand Kumar
Pujara, Naisarg
Kumeria, Tushar
Strounina, Ekaterina
Nunes, Rute
Costa, Ana
Sarmento, Bruno
Hasnain, Sumaira Z.
Ross, Benjamin P.
Popat, Amirali
author_sort Abeer, Muhammad Mustafa
collection PubMed
description Type 2 diabetes makes up approximately 85% of all diabetic cases and it is linked to approximately one-third of all hospitalisations. Newer therapies with long-acting biologics such as glucagon-like peptide-1 (GLP-1) analogues have been promising in managing the disease, but they cannot reverse the pathology of the disease. Additionally, their parenteral administration is often associated with high healthcare costs, risk of infections, and poor patient adherence associated with phobia of needles. Oral delivery of these compounds would significantly improve patient compliance; however, poor enzymatic stability and low permeability across the gastrointestinal tract makes this task challenging. In the present work, large pore dendritic silica nanoparticles (DSNPs) with a pore size of ~10 nm were prepared, functionalized, and optimized in order to achieve high peptide loading and improve intestinal permeation of exenatide, a GLP-1 analogue. Compared to the loading capacity of the most popular, Mobil Composition of Matter No. 41 (MCM-41) with small pores, DSNPs showed significantly high loading owing to their large and dendritic pore structure. Among the tested DSNPs, pristine and phosphonate-modified DSNPs (PDSNPs) displayed remarkable loading of 40 and 35% w/w, respectively. Furthermore, particles successfully coated with positively charged chitosan reduced the burst release of exenatide at both pH 1.2 and 6.8. Compared with free exenatide, both chitosan-coated and uncoated PDSNPs enhanced exenatide transport through the Caco-2 monolayer by 1.7 fold. Interestingly, when a triple co-culture model of intestinal permeation was used, chitosan-coated PDSNPs performed better compared to both PDSNPs and free exenatide, which corroborated our hypothesis behind using chitosan to interact with mucus and improve permeation. These results indicate the emerging role of large pore silica nanoparticles as promising platforms for oral delivery of biologics such as exenatide.
format Online
Article
Text
id pubmed-6723263
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67232632019-09-10 Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide Abeer, Muhammad Mustafa Meka, Anand Kumar Pujara, Naisarg Kumeria, Tushar Strounina, Ekaterina Nunes, Rute Costa, Ana Sarmento, Bruno Hasnain, Sumaira Z. Ross, Benjamin P. Popat, Amirali Pharmaceutics Article Type 2 diabetes makes up approximately 85% of all diabetic cases and it is linked to approximately one-third of all hospitalisations. Newer therapies with long-acting biologics such as glucagon-like peptide-1 (GLP-1) analogues have been promising in managing the disease, but they cannot reverse the pathology of the disease. Additionally, their parenteral administration is often associated with high healthcare costs, risk of infections, and poor patient adherence associated with phobia of needles. Oral delivery of these compounds would significantly improve patient compliance; however, poor enzymatic stability and low permeability across the gastrointestinal tract makes this task challenging. In the present work, large pore dendritic silica nanoparticles (DSNPs) with a pore size of ~10 nm were prepared, functionalized, and optimized in order to achieve high peptide loading and improve intestinal permeation of exenatide, a GLP-1 analogue. Compared to the loading capacity of the most popular, Mobil Composition of Matter No. 41 (MCM-41) with small pores, DSNPs showed significantly high loading owing to their large and dendritic pore structure. Among the tested DSNPs, pristine and phosphonate-modified DSNPs (PDSNPs) displayed remarkable loading of 40 and 35% w/w, respectively. Furthermore, particles successfully coated with positively charged chitosan reduced the burst release of exenatide at both pH 1.2 and 6.8. Compared with free exenatide, both chitosan-coated and uncoated PDSNPs enhanced exenatide transport through the Caco-2 monolayer by 1.7 fold. Interestingly, when a triple co-culture model of intestinal permeation was used, chitosan-coated PDSNPs performed better compared to both PDSNPs and free exenatide, which corroborated our hypothesis behind using chitosan to interact with mucus and improve permeation. These results indicate the emerging role of large pore silica nanoparticles as promising platforms for oral delivery of biologics such as exenatide. MDPI 2019-08-19 /pmc/articles/PMC6723263/ /pubmed/31430872 http://dx.doi.org/10.3390/pharmaceutics11080418 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Abeer, Muhammad Mustafa
Meka, Anand Kumar
Pujara, Naisarg
Kumeria, Tushar
Strounina, Ekaterina
Nunes, Rute
Costa, Ana
Sarmento, Bruno
Hasnain, Sumaira Z.
Ross, Benjamin P.
Popat, Amirali
Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide
title Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide
title_full Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide
title_fullStr Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide
title_full_unstemmed Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide
title_short Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide
title_sort rationally designed dendritic silica nanoparticles for oral delivery of exenatide
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723263/
https://www.ncbi.nlm.nih.gov/pubmed/31430872
http://dx.doi.org/10.3390/pharmaceutics11080418
work_keys_str_mv AT abeermuhammadmustafa rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide
AT mekaanandkumar rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide
AT pujaranaisarg rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide
AT kumeriatushar rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide
AT strouninaekaterina rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide
AT nunesrute rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide
AT costaana rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide
AT sarmentobruno rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide
AT hasnainsumairaz rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide
AT rossbenjaminp rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide
AT popatamirali rationallydesigneddendriticsilicananoparticlesfororaldeliveryofexenatide